SugarCone Biotech

JUNE 10, 2024

Targeting 4-1BB remained of interest to the immuno-oncology field as cell culture experiments and tumor models in mice suggested that robust anti-tumor immune responses could be triggered by anti-4-1BB antibody therapies. This is the T cell type most closely associated with anti-tumor immune responses.

Immune Response 88

Immune Response Production Regulations Clinical Trials 88

Drug Target Review

APRIL 17, 2024

HLA are the critical molecules that our immune systems use to present peptides to T cells and facilitate recognition and killing in immune responses to pathogens. HLA-II presents peptides to CD4 T cells thought to be important for indirectly helping immune responses and facilitating antibody production.

Immune Response 106

Immune Response Laboratories DNA Virus 106

The Pharma Data

OCTOBER 14, 2021

Biogen today announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS). Biogen today announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS). Using data from the MS PATHS network in the U.S.,

Vaccine 52

Vaccine Therapies Immune Response Disease 52

Drug Target Review

MAY 14, 2024

How do hydrophobicity, electrostatic charge, and secondary confirmation of helical polypeptides influence the stimulation of innate immune pathways in antigen-presenting cells (APCs)? What potential therapeutic advantages do the engineered cationic polypeptides offer in the context of generating antitumour immune responses?

Engineering 59

Engineering Immune Response FDA Approval Clinical Trials 59

Conversations in Drug Development Trends

JUNE 21, 2024

This year, Matt Cooper, PhD , our Executive Director, Therapeutic Strategy Lead, Oncology, attended and found the presentations around antibody-drug conjugates (ADCs) and tumor-infiltrating lymphocytes (TILs) to be of great interest to the future of oncology therapeutics. Interested in hearing more insights from Matt?

Clinical Trials 64

Clinical Trials Therapies Clinical Research Immune Response 64

Drug Target Review

JANUARY 15, 2024

Additionally, in evaluating the effectiveness of our initial pipeline asset, we sought tumours suitable for intratumoural injection that present surface-accessible lesions. The preclinical results demonstrated significant immune responses and tumour regression. Activation of the ELANE pathway appears pivotal.

Treatment 106

Treatment Immune Response Therapies Clinical Trials 106

Drug Target Review

OCTOBER 19, 2023

A potential game-changer in medicine The implications of this research are vast, potentially transforming the way we treat a variety of diseases involving both the immune and nervous systems. In the absence of IL-31, these nerve cells failed to control the immune system, leading to unchecked inflammation.

Immune Response 104

Immune Response Regulations Treatment Therapies 104

Drug Target Review

JUNE 6, 2023

We are in an era of immuno-oncology (IO) revolution with many approved therapies now available to treat a broad range of cancers. Generally, IO has been focused on harnessing the anti-tumour activity of certain cancer-fighting T-cells , a key cell type involved in the adaptive immune defense system.

Engineering 98

Engineering Immune Response Biochemical Pharmacology Clinical Trials 98

The Pharma Data

NOVEMBER 18, 2020

Presentations to highlight the OBI-833 Phase 1 clinical study results in non-small cell lung cancer (NSCLC) and the dose escalation cohort. These results will be presented by the lead investigators of OBI Pharma’s novel anti-Globo H therapeutic cancer vaccine, OBI-833. ” Presentation number: 397P / Poster: ID 680.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

Drug Target Review

JUNE 9, 2023

This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.

Treatment 106

Treatment Packaging Clinical Research Therapies 106

Drug Target Review

JANUARY 15, 2024

The pathogenesis of COPD is based on the innate and adaptive inflammatory immune response to the inhalation of toxic particles and gases. Dr Yuri concluded: “We believe that our study makes an important contribution to the literature by presenting a faster and more efficient method of exploring blastocyst complementation.”

Immune Response 113

Immune Response Disease Science Therapies 113

The Pharma Data

OCTOBER 19, 2020

Two presentations will be delivered by Nanobiotix and two will be delivered by the University of Texas MD Anderson Cancer Center. NBTXR3 is a novel radioenhancer composed of functionalized hafnium oxide nanoparticles that is administered via one-time intra-tumoral injection and activated by radiation therapy.

Clinical Trials 52

Clinical Trials Immune Response Trials Therapies 52

Drug Target Review

SEPTEMBER 11, 2023

While the concept of removing mucins from cancer cells seems promising, mucins are present in various forms on all mammalian cells. This sugar-coated mucin binding to checkpoint receptors signals that the cancer cell poses no threat, consequently blocking the immune response.

Immune Response 116

Immune Response Research Engineering Virus 116

The Pharma Data

SEPTEMBER 28, 2020

Australian biotech Ena Respiratory has revealed new data demonstrating that its novel nasal spray almost halted replication of the SARS-CoV-2 in animals when used as a prophylactic, showing potential to improve immune response when used alongside COVID-19 vaccines. . We’ve been amazed with just how effective our treatment has been.

Immune Response 52

Immune Response Small Molecule Virus Vaccine 52

DrugBank

MAY 6, 2024

Unlike conventional chemical-based medicines, biologics offer targeted therapies derived from living cells, which can result in more effective and personalized treatments. A Wave of Innovations The year 2024 has already proven to be significant for the field of biologics, witnessing a notable increase in FDA approvals.

FDA Approval 65

FDA Approval Therapies Treatment Clinical Trials 65

The Pharma Data

APRIL 8, 2021

Leadership in DNA damage response demonstrated in multiple presentations for AZD5305, a next-generation PARP1 selective inhibitor. Key presentations will include: Structural disclosure and key preclinical data for AZD5305, a next-generation PARP1 selective inhibitor.

DNA 52

DNA Immune Response Therapies Treatment 52

The Pharma Data

FEBRUARY 18, 2022

Findings show that the percentage of patients achieving clinical remission, clinical response, endoscopic improvement and corticosteroid-free remission was maintained through Week 142. Additional Bristol Myers Squibb-sponsored abstracts presented at the ECCO 2022 Congress can be accessed online here. About Ulcerative Colitis.

Clinical Trials 40

Clinical Trials Treatment Immune Response Disease 40

The Pharma Data

MARCH 8, 2022

The study was published online in advance in the journal Molecular Therapy – Nucleic Acids and is now available in the final version. In this way, the viral RNA escapes early recognition by the central antiviral immune-receptor RIG-I. RIG-I-induced innate antiviral immunity protects mice from lethal SARS-CoV-2 infection.

Clinical Pharmacology 52

Clinical Pharmacology Immune Response RNA Virus 52

The Pharma Data

NOVEMBER 9, 2020

The results were presented at The Society for the Immunotherapy of Cancer 35 th Anniversary Annual Meeting. Taken together, these barriers present a significant unmet need to improve the efficacy ICIs and expand their potentially curative benefits to more patients with advanced cancers. Addressing Unmet Needs in Cancer Immunotherapy.

Immune Response 40

Immune Response Therapies Clinical Trials Treatment 40

The Pharma Data

MARCH 9, 2021

Novartis and CANOPY-2 investigators will analyze the study data and are expected to submit its findings for presentation at an upcoming medical meeting. CANOPY-A, another Phase III study, is investigating canakinumab as an adjuvant therapy and has enrolled more than 950 patients to date and is expected to enroll a total of 1,500 patients 3.

Treatment 52

Treatment Immune Response Trials Clinical Trials 52

The Pharma Data

JULY 6, 2021

New research from first-in-class marketed and investigational therapies in hemophilia, immune thrombocytopenia and acquired thrombotic thrombocytopenic purpura will be presented. Sanofi’s two marketed extended half-life factor replacement therapies shifted a two-decades-old treatment paradigm when launched in 2014.

Therapies 52

Therapies Pharmacokinetics RNA Treatment 52

Olympian Clinical Research

DECEMBER 19, 2023

These patches present more than physical discomfort. Advanced Medical Treatments and Research Treating pediatric plaque psoriasis involves personalized approaches, with topical therapies and light therapy being common initial treatments. This is about more than just trying new therapies.

Clinical Research 52

Clinical Research Clinical Trials Treatment Immune Response 52

The Pharma Data

DECEMBER 13, 2020

Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced SYNB1891 has advanced into the combination therapy stage of the ongoing Phase 1 trial. Results of the SYNB1891 Phase 1 study will be presented at a future medical meeting. CAMBRIDGE, Mass. ,

Immune Response 40

Immune Response Treatment Engineering Clinical Trials 40

The Pharma Data

JANUARY 25, 2021

25, 2021 — Giving melanoma patients a “personalized” vaccine can prompt an anti-tumor immune response that lasts for years, an early study finds. But it builds on earlier work showing it is possible to spur the immune system to respond to an individual’s unique tumor. MONDAY, Jan.

Vaccine 52

Vaccine Immune Response Medical Schools Clinical Trials 52

SugarCone Biotech

MAY 28, 2019

Lymphoid Structures Drive Immune Checkpoint Therapy and the Efficacy of Cellular Therapeutics (a reboot from 2020) We’d been hearing the rumors for months. But first, these new papers are gorgeous: The study presented by Petitprez et al. is focused on the response of sarcomas to immunotherapy ( [link] ).

Immune Response 52

Immune Response Therapies Production Vaccine 52

The Pharma Data

MARCH 8, 2021

Novartis and CANOPY-2 investigators will analyze the study data and are expected to submit its findings for presentation at an upcoming medical meeting. CANOPY-A, another Phase III study, is investigating canakinumab as an adjuvant therapy and has enrolled more than 950 patients to date and is expected to enroll a total of 1,500 patients 3.

Immune Response 52

Immune Response Clinical Trials Trials Treatment 52

Drug Target Review

APRIL 3, 2024

Our company has identified a new role for Growth Differentiation Factor 15 (GDF-15) as a potent local immunosuppressor mediating cancer resistance to therapy. In this regard, AI presents itself as a valuable ally, offering the potential to bolster our endeavours and ensure successful outcomes.

Science 106

Science Clinical Development Treatment DNA 106

The Pharma Data

OCTOBER 14, 2020

APX005M is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. APX005M targets CD40, a co-stimulatory receptor that is essential for activating both innate and adaptive immune systems. Binding of APX005M to CD40 on antigen presenting cells (i.e., About Apexigen.

Treatment 40

Treatment Immune Response Clinical Trials Clinical Development 40

The Pharma Data

DECEMBER 10, 2020

The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. The study showed this broad immune response led to the complete clearance of the virus in a matter of days after infection of previously-vaccinated primates. link] 1. About ImmunityBio.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

MARCH 27, 2023

Entyvio ® should be used only in patients with inadequate response to conventional treatment. This approval is based on the MLN0002SC-3027 and MLN0002SC-3030 clinical trials, which are international Phase III trials to evaluate the efficacy and safety of Entyvio SC as a maintenance therapy. Injection 108mg / Syringes for S.C.

Treatment 40

Treatment Marketing Pharmaceutical Companies Immune Response 40

The Pharma Data

MARCH 25, 2021

“Immune checkpoint inhibitors alone or in combination have transformed treatment and improved survival rates for patients with metastatic or unresectable melanoma. LAG-3 regulates an inhibitory immune checkpoint pathway that limits the activity of T cells, leading to an impaired ability to attack tumor cells.

Trials 52

Trials Clinical Trials Immune Response Therapies 52

Drug Target Review

FEBRUARY 28, 2024

Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. Preclinical research on γδ T cells has made great strides since the cells were first identified in the 1980s, with γδ T-cell therapies from several companies, including IN8bio, now in or nearing clinical trials for various cancers.

Therapies 105

Therapies Engineering Molecular Biology Science 105

Olympian Clinical Research

NOVEMBER 16, 2022

In its early stages, HS often presents as a small, pea-sized lump in one place. HS is believed to develop due to an immune response that generates too much inflammation. People with HS may have an overactive immune system, which causes their bodies to overreact to the presence of a blocked hair follicle. Heal breakouts.

Treatment 52

Treatment Clinical Research Immune Response Therapies 52

LifeSciVC

MARCH 1, 2023

This was recently underscored by Nurix Therapeutics who presented multiple posters at the Society for Immunotherapy of Cancer Annual Meeting on their Phase One CBL-B program. And in early January, we bolstered the potential of CBL-B inhibition by announcing clearance of our first IND based on robust preclinical data.

Small Molecule 52

Small Molecule Immune Response DNA Therapies 52

Codon

FEBRUARY 13, 2024

Tom Ireland writes about the companies and technologies that are reimagining phage therapy. Soon after its publication, scientists, journalists, and investors were revisiting ‘phage therapy’ as a promising alternative to our failing antibiotics. Read it on our website here. Illustration by David S. Fast forward to 2023.

Therapies 118

Therapies DNA Virus Clinical Trials 118

The Pharma Data

OCTOBER 26, 2020

Testing Therapies, Antivirals and Vaccines. Novavax will present data from an ongoing Phase I/II clinical trial, including new Phase II reactogenicity data from its COVID-19 vaccine candidate. CoV2373 on Friday during the CDC’s Advisory Committee on Immunization Practices’ (ACIP) meeting. Please read more here. .

Vaccine 52

Vaccine FDA Approval FDA Clinical Trials 52

The Pharma Data

NOVEMBER 12, 2020

The CALAVI trials were launched based on preclinical and early clinical evidence that Calquence could decrease the hyperinflammatory immune response and improve clinical outcomes in patients hospitalised with respiratory symptoms of COVID-19.1 The data will be presented in due course.

Trials 52

Trials Clinical Trials Immune Response FDA Approval 52